このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Sinco Pharmaceuticals Holdings 将来の成長

Future 基準チェック /06

現在、 Sinco Pharmaceuticals Holdingsの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Healthcare 収益成長	17.0%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

更新なし

Recent updates

Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings

Apr 02

Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks

Mar 08

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

Nov 07

A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Jun 26

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

May 30

Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet

Oct 26

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today

Feb 04

I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease

Oct 25

Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings

Jun 10

Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt

May 24

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock

Apr 20

We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings

Feb 16

How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 11

Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?

Dec 07

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Sinco Pharmaceuticals Holdings は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

SEHK:6833 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2023	2,540	42	324	354	N/A
9/30/2023	2,386	35	340	383	N/A
6/30/2023	2,232	27	355	413	N/A
3/31/2023	2,252	48	189	244	N/A
12/31/2022	2,272	69	22	75	N/A
9/30/2022	2,289	96	145	193	N/A
6/30/2022	2,307	122	268	312	N/A
3/31/2022	2,165	128	275	309	N/A
12/31/2021	2,024	135	282	306	N/A
9/30/2021	2,142	148	294	307	N/A
6/30/2021	2,261	161	305	308	N/A
3/31/2021	2,155	140	221	222	N/A
12/31/2020	2,050	118	137	137	N/A
9/30/2020	1,664	79	-40	-40	N/A
6/30/2020	1,277	41	-218	-217	N/A
3/31/2020	1,227	32	-114	-113	N/A
12/31/2019	1,176	24	-10	-10	N/A
9/30/2019	1,045	-97	135	136	N/A
6/30/2019	915	-217	281	281	N/A
3/31/2019	934	-249	268	269	N/A
12/31/2018	953	-281	255	256	N/A
9/30/2018	960	-242	38	40	N/A
6/30/2018	966	-203	-179	-177	N/A
3/31/2018	886	-195	-271	-268	N/A
12/31/2017	807	-186	-363	-359	N/A
9/30/2017	755	-115	N/A	-243	N/A
6/30/2017	704	-43	N/A	-127	N/A
3/31/2017	781	-12	N/A	-78	N/A
12/31/2016	859	19	N/A	-30	N/A
9/30/2016	958	36	N/A	-6	N/A
6/30/2016	1,057	52	N/A	17	N/A
3/31/2016	1,076	61	N/A	32	N/A
12/31/2015	1,096	70	N/A	46	N/A
9/30/2015	1,120	77	N/A	87	N/A
6/30/2015	1,144	84	N/A	128	N/A
3/31/2015	1,047	77	N/A	91	N/A
12/31/2014	950	69	N/A	53	N/A
12/31/2013	532	37	N/A	78	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 6833の予測収益成長が貯蓄率 ( 2.2% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: 6833の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: 6833の収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: 6833の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: 6833の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 6833の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Sinco Pharmaceuticals Holdings 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Sinco Pharmaceuticals Holdings Limited, Annual General Meeting, May 16, 2024

Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings

Dividend reduced to HK$0.0039

Sinco Pharmaceuticals Holdings Limited Proposes Final Cash Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024

Sinco Pharmaceuticals Holdings Limited Resignation of Li Kin Wai as Joint Company Secretary and Appointment of Peng Yunlu as Executive Director

Sinco Pharmaceuticals Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Now 20% overvalued

Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks

Now 20% overvalued

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

New minor risk - Share price stability

First half 2023 earnings released: EPS: CN¥0.01 (vs CN¥0.03 in 1H 2022)

Now 20% undervalued after recent price drop

Sinco Pharmaceuticals Holdings Limited to Report Q2, 2023 Results on Aug 30, 2023

A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

Full year 2022 earnings released: EPS: CN¥0.034 (vs CN¥0.078 in FY 2021)

Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet

First half 2022 earnings released: EPS: CN¥0.03 (vs CN¥0.044 in 1H 2021)

Sinco Pharmaceuticals Holdings Limited to Report First Half, 2022 Results on Aug 31, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS: CN¥0.078 (vs CN¥0.07 in FY 2020)

Sinco Pharmaceuticals Holdings Limited, Annual General Meeting, May 13, 2022

Investor sentiment improved over the past week

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today

Sinco Pharmaceuticals Holdings Limited (SEHK:6833) entered into a letter of interest to acquire Deyang Demei Medical Aesthetic Clinic from Jiang Biao, Jiang Min and Jiang Jun.

Investor sentiment deteriorated over the past week

Sinco Pharmaceuticals Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 206.4 million.

Investor sentiment improved over the past week

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease

First half 2021 earnings released: EPS CN¥0.044 (vs CN¥0.019 in 1H 2020)

Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings

Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt

Full year 2020 earnings released: EPS CN¥0.07 (vs CN¥0.014 in FY 2019)

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock

Joint Company Secretary has left the company

Full year 2020 earnings released: EPS CN¥0.07 (vs CN¥0.014 in FY 2019)

Sinco Pharmaceuticals Holdings Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: HK$0.32

We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings

Sinco Pharmaceuticals Holdings Limited Announces Management Changes

How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?

Sinco Pharmaceuticals Holdings Limited Announces Board Changes

New 90-day low: HK$0.26

Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?

Sinco Pharmaceuticals Holdings Limited Appoints Jin Min as Co-Chief Executive Officer

New 90-day high - HK$0.30

Sinco Pharmaceuticals Holdings Limited to Report Q2, 2020 Results on Aug 28, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘